Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PVSP Over 400 Cannabis Products
https://www.leafly.com/brands/artizen-cannabis
$PVSP utilize project management to translate, plan, and execute strategies to help achieve successful submissions, adhere to agency compliance, and remediate identified issues.
$GTCH #AIEYE #Podcast; #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $AI) #artificialintelligence #AI #Stocks #markets #Finance #Business #investing #machinelearning #tech #Technology
https://investorideas.com/news/2022/artificial-intelligence/01191GTCH-AI.asp
$PVSP Freedom Cannabis CEO, JohnFrank Potestio: “This provides our company with a very important foothold in the US market that can be developed even further as our two companies begin to collaborate.”
The two companies will also explore a potential merger in the future, depending on market conditions and regulatory approvals, that would significantly increase market share in North America. A potential merger would be dependent on due diligence by both parties, Freedom Cannabis pursuing a public offering in Canada, and legalization of cannabis at the federal level in the US.
“We are very pleased to have formed a working relationship with Artizen,” explained JohnFrank Potestio. “Artizen shares the same values as Freedom Cannabis and is dedicated to becoming one of the leading brands in North America. This provides a significant opportunity for Freedom to access the US market while continuing to build its brand in Canada.”
$GTCH Latest News and Headlines https://www.barchart.com/stocks/quotes/GTCH/news
The sustainable energy sector is growing and companies like Clean Vision Corporation, a leader in the hydrogen market, are working to advance the clean energy sector. Their subsidiary, Clean-Seas Inc., supports emerging ventures in the green economy. Clean Vision is moving further with continuous growth. It has seen a spike and still going up! Buy now before it's too late!
https://pubcoinsight.com/2022/06/10/clean-energy-3/
$PVSP utilize project management to translate, plan, and execute strategies to help achieve successful submissions, adhere to agency compliance, and remediate identified issues.
$GTCH Cybersecurity Solutions Becoming Pervasive as Threats Escalate https://www.investorideas.com/news/2022/defense/04040Cybersecurity.asp#.YksLnHVTdbQ.twitter
$PVSP With over 200,000 square feet of grow facility space under management, supporting a 30-person distribution center, and licensing the Artizen™ brand to cultivators in Washington State, ZAM is poised to expand its reach across the West coast and into Arizona and other recreational states.
$GTCH There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.
https://www.benzinga.com/pressreleases/22/06/g27562448/gbt-is-researching-the-development-of-a-unified-machine-learning-driven-automated-ic-design-enviro
SFLMaven Corp. - $SFLM announced unaudited performance results for the week ended Thursday, June 2, 2022, which featured strong demand leading to $286k in total weekly sales.
The June 2 auction was highlighted by the sale of a heavy 18K WG 28.64CT diamond sapphire tourmaline pearl formal necklace for $7,988 and a vintage heavy 14K/Platinum 5.0CT diamond and sapphire filigree cuff bracelet for $4,549.
https://finance.yahoo.com/news/sflmaven-announces-robust-week-powering-123000447.html
$PVSP partnered with a national cultivation group in its effort to upgrade all facilities and grow SOPs with an objective to increase per square foot output by 50%
$PVSP Intereactive Chart https://www.barchart.com/stocks/quotes/PVSP/interactive-chart
$RGGI Robotics: Nice demo video on the capabilities and benefits of the company's new Pull Buddy and BotWay Express systems:
Pull Buddy & BotWay Express
CBD oils and products have become a popular, natural way to treat a long list of chronic ailments. Look at CBD companies like CV Sciences (OTC: CVSI), Village Farms (NASDAQ: VFF), and Endexx (OTC: $EDXC). EDXC is set to hit a spike soon. get in before that happens!
www.endexx.com
$PVSP partnered with a national cultivation group in its effort to upgrade all facilities and grow SOPs with an objective to increase per square foot output by 50%
$GTCH Their 3D microchip patent was filed on March 5, 2019, and was granted as of December 1, 2020 by the USPTO; U.S. Patent No. 10,854,763. The continuation application, assigned number 17102928, was filed on November 24, 2020. The Company’s intent in filing the continuation is to broaden the protection of its main IP concepts. It is GBT’s goal to further develop advancements in this domain through the use of the 3D, multidimensional design, utilizing more space on the silicon wafer, enabling manufacturing of larger ICs, with higher performance, lower power consumption and cheaper. This technology can be particularly advantageous for fabless design houses to design advanced microchips with much lower cost.
“We continue to seek to broaden our 3D, multiplanar chip IP with our continuation application. One of the major areas that we plan to enhance is the mount planes of the semiconductor wafers. We believe the idea of mounting on vertical and horizontal planes creates a whole world of possibilities when designing and manufacturing multiplanar microchips. If successfully implemented, we believe these chips will be able to contain more circuitries, operating with higher performance and consuming less power. We believe this is an innovative concept, designed to be accompanied with scaling down ICs size to fit into smaller electronic devices. Redesigning and manufacturing microchips with multiplanetary architecture would enable placing more circuitries on same or smaller space silicon dies, which would expect to significantly lower their cost. The 3D microchip continuation application is planned to broaden the original patent with design and fabrication concepts. With the ever-growing microchip’s complexity, demand for less power, faster performance and smaller size, we believe that the presented patent’s technology can be an efficient solution, enabling economical IC’s design and manufacturing, creating new horizons and standards,” provided Danny Rittman, the Company’s CTO.
SFLMaven Corp. - SFLM announced the grand opening of their unique and dynamic metaverse store in Decentraland. While the current store offers sales directly linked to the SFLMaven highly successful jewelry eBay store, the metaverse store is being developed to become the premier place for finding metaverse jewelry. This metaverse store opening was long expected. This is gonna blow up $SFLM. Buy now before that happens.
https://finance.yahoo.com/news/sflmaven-launches-jewelry-store-major-123000476.html
$SNGX News: Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
June 1, 2022 (PR Newswire)
Paper published in the Journal Structure
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the binding of its Innate Defense Regulator (IDR), dusquetide, to the p62 protein. Dusquetide has demonstrated anti-infective, anti-tumor and anti-inflammatory actions in multiple animal models by modulating the body's own innate immune system. Dusquetide previously demonstrated significant benefits in reducing the duration of severe oral mucositis (SOM) in a Phase 2 clinical trial and reduction in SOM rates in the per protocol population in a Phase 3 study. In addition to the reduction of SOM, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer (HNC). This was corroborated by more recent findings confirming dusquetide's anti-tumor activity in xenograft models of breast cancer.
Based on the biological proof of principle shown both nonclinically and clinically with dusquetide, a novel synthetic peptide that modulates the body's innate immune system, Soligenix continues to explore product opportunities, both in the reduction of oral mucositis in HNC and as a potential anti-cancer treatment. Dusquetide binds to p62 or SQSTM-1, a scaffold protein implicated in a number of intracellular signaling networks implicated in tumor cell survival, including autophagy. This recent publication elaborates on the direct interaction of dusquetide with p62, as well as some of the direct downstream consequences of that interaction, consistent with its observed anti-infective, anti-tumor and anti-inflammatory activities. This information advances the understanding of dusquetide's novel mechanism of action and supports the development of analogs related to dusquetide.
"Soligenix continues to pursue potential product opportunities with our new chemical entity dusquetide," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With the supportive data from the Phase 2 and 3 oral mucositis trials, and the nonclinical anti-tumor efficacy demonstrated, we will continue to pursue potential partnership opportunities for this novel molecule and its potential analogs."
About Dusquetide
Dusquetide (the active ingredient in SGX942) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens. It also accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- and/or radiation therapy. Preclinical efficacy and safety has been demonstrated in numerous animal disease models including mucositis, colitis, macrophage activation syndrome (MAS) as well as bacterial infections, including melioidosis. Potential anti-tumor activity has been demonstrated in in vitro and in vivo xenograft studies.
SGX942 has demonstrated safety and tolerability in a Phase 1 clinical study in 84 healthy human volunteers. Positive efficacy results were demonstrated in an exploratory Phase 2 clinical study in 111 patients with oral mucositis due to CRT for HNC, including potential long-term ancillary benefits. The Phase 3 multinational, placebo-controlled, randomized study evaluated the impact of dusquetide on the duration of SOM in 268 subjects with squamous cell carcinoma of the oral cavity and oropharynx, receiving CRT. While the Phase 3 clinical study did not achieve the required level of statistical significance (pless-than or equal to 0.05) in its primary endpoint of median duration of SOM, a clinically meaningful reduction was observed, including a statistically significant reduction in the duration of SOM in the per-protocol population (p=0.049), consistent with the findings in the Phase 2 trial.
SGX942 has received Fast Track Designation from the FDA for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in HNC patients, as well as Promising Innovative Medicine designation in the United Kingdom by the Medicines and Healthcare products Regulatory Agency for the treatment of severe oral mucositis in HNC patients receiving CRT. In addition, products containing the same active ingredient, dusquetide, have been granted Fast Track Designation as an adjunctive therapy with other antibacterial drugs, for the treatment of melioidosis and Orphan Drug Designations in the treatment of MAS and the treatment of acute radiation syndrome.
Soligenix has a strong intellectual property position in the IDR technology platform, including composition of matter for dusquetide and related analogs. Dusquetide was developed pursuant to discoveries made by Professors B. Brett Finlay, PhD and Robert Hancock, PhD of the University of British Columbia, Canada. Soligenix has received partial funding from NIH for its oral mucositis clinical studies. The Phase 2 study was supported with a Phase I SBIR grant (#R43DE024032) award, with the Phase 3 study being supported by a Phase II SBIR grant (#R44DE024032) award.
In addition, a high level review of the IDR technology platform is available here.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax(R) will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R). Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
https://c212.net/c/img/favicon.png?sn=PH74370&sd=2022-06-01
View original content:https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html
SOURCE Soligenix, Inc.
$GTCH Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/GTCH/cheat-sheet
$PVSP Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/PVSP/cheat-sheet
$GTCH Cybersecurity Solutions Becoming Pervasive as Threats Escalate https://www.investorideas.com/news/2022/defense/04040Cybersecurity.asp#.YksLnHVTdbQ.twitter
$PVSP DESCRIPTION
We provide business consulting and marketing services to public companies. More than 100 companies have purchased space on our website https://privateequitymarkets.us/. Our website features publicly traded companies and highlights the mining, technology, bio-tech, green-tech and cannabis industries. Services include free listings of press releases and a news feed.
$PVSP ZAM provides consulting, leasing, intellectual property licensing and other long-term arrangements to cannabis operators, including management of the Artizen™ brand assets
$PVSP
0.0018 + 0.00005 (2.86%)
Volume: 525,228 @05/26/22 12:16:51 PM EDT
CleanVision Corp - CLNV Got Featured Today on PubCo Insight.
"A quieter last few weeks from CleanVision Corp after finishing off a busy month of March and April. Company CEO, Dan Bates and the subsidiary Clean Seas were hard at work forging partnerships with local governments in Morocco, Sri Lanka, and Puerto Rico. Just this past week, the pilot Pyrolysis project in Hyderabad, India officially was commissioned and will begin its 1.2 ton per day conversion of plastic waste into clean energy fuels. Look for more updates from the company as these projects begin to take shape in their respective markets." PubCO Insight Wrote.
$PVSP ZAM is a diversified asset management company, founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM provides services to several customers in Washington State, including four licensed cultivation facilities and one licensed processing facility, under a series of consulting, leasing, intellectual property licensing and other long-term agreements. ZAM is also responsible for development and licensing of one of the most successful cannabis brands, Artizen™.
The first independent cultivator’s flagship facility was custom designed and built in Lacey, Washington in 2014. Artizen branded products were licensed to and sold from this facility as early as 2015. The strain collection launched during that time immediately caught the attention of connoisseurs and experienced shop owners and budtenders — folks who know premium cannabis.
$GTCH Security Details https://www.otcmarkets.com/stock/GTCH/security
$PVSP April 26, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets, announces the Schedule of the 30th Emerging Growth Conference.
The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth https://www.otcmarkets.com/stock/PVSP/news/CEOs-Presenting-at-the-Emerging-Growth-Conference-on-April-27-Register-Now?id=353784
$SNGX: A significant development for with patent allowance for thermostabilized vaccines. The issue of transporting vaccines under difficult to maintain temperature conditions is of high importance around the world.
Soligenix Receives US Patent Allowance For Its Thermostabilized Vaccine Platform
May 23, 2022 (Benzinga)
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are directed to unique, proprietary compositions and methods directed to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to filovirus vaccines (as mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus) as well as a SARS-CoV-2 vaccine.
The candidate filovirus vaccines have been previously shown to protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs. Lyophilization of the antigens within monovalent vaccine formulations has also been demonstrated to thermostabilize the antigens at temperatures as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to 12 weeks, enabling storage at ambient temperature. No currently licensed lyophilized vaccine that contains an adjuvant is presented in a single vial format and there are few reports of successfully using nano-emulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s) and a nanoemulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity. This most recent milestone confirms that, in the context of lethal challenge with Sudan ebolavirus, complete protection is maintained with the thermostabilized formulation.
"Filoviruses such as Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain. There are no vaccines for either Sudan or Marburg viruses, while approved vaccines for Zaire ebolavirus are constrained by cold chain logistics. Availability of a single-vial, heat stable vaccine would significantly enhance global public health preparedness or response to a new outbreak, at its source," stated Axel Lehrer, PhD, Associate Professor, Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai?i at Manoa (UHM). "Our work to date has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can then be stored at temperatures exceeding 100 degrees Fahrenheit. Having a vaccine platform such as this available has the potential to accelerate worldwide vaccination campaigns addressing future health emergencies, including other global pandemics as seen with COVID-19."
"Our next generation combined vaccine platform includes three major components: a robust protein manufacturing process that has been demonstrated on multiple protein antigens, a novel nanoemulsion adjuvant which induces broad immunity and a formulation procedure which enables thermostabilization of the combination of adjuvant and antigen in a single vial," stated Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix. "Elements of this vaccine platform have been utilized in our ricin toxin, filovirus and COVID-19 vaccine candidates, indicating its broad applicability. The ability to package more than one vaccine candidate in a single vial platform further adds to their developability, whether as a multivalent or individual monovalent vaccine, particularly against Sudan ebolavirus and Marburg marburgvirus where there are currently no available vaccines."
Work to date has demonstrated the compatibility of lyophilizing both antigen and adjuvant in the same vial, with reconstitution with sterile water for injection immediately prior to use. This simple delivery format, as well as the compatibility with ambient storage, significantly reduces logistical hurdles when vaccinating large groups of individuals as required for example when addressing a global pandemic or for the deployment of vaccines in outbreaks occurring in remote areas or with unreliable power supply.
Under the Company's Public Health Solutions business segment, ongoing collaborations with Dr. Lehrer, have demonstrated the feasibility of developing thermally-stable subunit protein vaccine formulations for filoviruses. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health (NIH) grant R01-AI132323 (awarded to the University of Hawaii) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
$CURR has very welcome news on positive clinical trial results with the company's delivery methodology for the important application of Vitamin D in Pediatric Patients. This can mean a lot of value with eventual commercial applications.
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic St
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)
CCHMC to Seek Formulary approval for CURE’s OTF Vitamin D Supplement in its Hospital Formulary
OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced positive finding from a study conducted at Cincinnati Children’s Hospital Medical Center (CCHMC) using CURE’s proprietary, single dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURE’s oral Vitamin D supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin D sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving HSCT.
To view the details of this study, visit the poster presentation on CURE’s website at https://curepharmaceutical.com/white-papers/
“The findings for our proprietary, oral thin film Vitamin D, which we brand as ImmunD3 NutriStrips, is quite remarkable for its ability to improve bone health and reduce complications in pediatric patients and brings additional hope to the parents and their children who undergo HSCT stem cell therapy, for life-threatening diseases,” said CURE Pharmaceutical CEO Rob Davidson. “If we can reduce the risks of complications by bringing these children up to optimal Vitamin D levels before surgery, and in the acute post-transplantation period, we’ve helped to reduce pain and suffering and potentially saved lives.”
Next Steps: Adding CURE’s oral Vitamin D to Formularies Nationwide
Since previous attempts to improve vitamin D deficiency in these young patients using additional doses and/or higher dosing of enteral vitamin D are often not successful, CCHMC is working with its Formulary to add CURE’s NutriStrip Vitamin D formulation to its list of approved treatments.
Davidson added: “We are also pleased that the CCHMC team found these results to be so compelling as to commence the process to include what we call “ImmunD3 Nutri-Strips™” in their hospital’s Formulary. In light of this advancement, we plan to reach out to other children’s hospitals around the U.S. in order to share these compelling findings and seek the addition of our proprietary Vitamin D into their Formularies.”
Using CURE’s proprietary delivery technology is important because it overcomes the numerous barriers that impede adequate replacement with conventional vitamin D therapy. Some of these obstacles include:
malabsorption secondary to gut GVHD
the inability to take capsules
Mucositis
Kidney disease
Liver disease
Infection
More About the Study
The CCHMC study found that compliance and tolerance likewise improved, with patients and parents expressing a preference for the strips. The median age of the study cohort was 8 years, with a range of 1-28 years old, dosing varied significantly, from 1 strip monthly to 4 strips weekly and all patients showed improvement in serum vitamin D levels by week 4 on study. The median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p Median vitamin D level at baseline was 29.4 ng/mL, significantly improved (p 0.0001) to 5.5ng/mL at the end of the study).
About Vitamin D and Pediatric Hematopoietic Stem Cell Transplantation Patients
Vitamin D is essential for bone health and has immunomodulatory properties. Most pediatric patients are vitamin D insufficient (<30 ng/mL) before HSCT. Standard supplementation strategies fail to achieve vitamin D sufficiency in the acute post-transplantation period, and there are scarce data to support optimal vitamin D supplementation in this patient population. This study, the poster of which can be found here: https://curepharmaceutical.com/white-papers/ sought to evaluate whether a single, oral, weight-based ultra-high dose of vitamin D was more effective than standard supplementation in achieving pre-HSCT vitamin D sufficiency and reducing the incidence of HSCT-related complications (acute graft-versus-host disease, veno-occlusive disease, and/or transplant-associated thrombotic microangiopathy) that are associated with immune-mediated endothelial damage. Secondary endpoints examined the immunomodulatory properties of vitamin D.
About CURE Pharmaceutical
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. Among CURE’s key products is its oral thin film, 40,000 IU dose Vitamin D, (Branded Nutri-Strips™ in the Retail Market). Each strip is hermetically sealed in airtight, grab-and-go packaging to eliminate chemical and structural breakdown and provide superior potency. Nutri-Strips™ are available online at https://www.nutristripnow.com/immund3
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statements
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements.
Contacts:
Investor Relations
investor@curepharma.com
(805) 410-9962 ext. 4
$GTCH is Enhancing qTerm’s Cybersecurity Technology to Provide a Higher Level of Data Protection For its Users
https://finance.yahoo.com/news/gbt-enhancing-qterm-cybersecurity-technology-130000725.html
$GTCH GBT Roadmaps The Development of a Wearable Version for Its qTerm Device https://newsfilter.io/a/87d4022ff93dfa7e6a3f5489e6d3eb42
$GTCH Cybersecurity Solutions Becoming Pervasive as Threats Escalate
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - April 4, 2022) - Investorideas.com, a global investor news source covering tech and cybersecurity stocks, issues a report on cybersecurity solutions and developments, featuring GBT Technologies Inc. (OTC Pink: GTCH), a small reporting tech company with a diverse portfolio of IP.
https://www.investorideas.com/news/2022/defense/04040Cybersecurity.asp
$PVSP With over $17 million in sales annually, Artizen branded cannabis products have established themselves as market leaders in various categories. As the brand is about to be offered in various recreational states, this is just one more award confirming its quality and market acceptance.
$GTCH GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.
https://seekingalpha.com/pr/18777328-gbt-s-ai-based-motion-detection-wireless-patent-granted
$PVSP Located in beautiful Port Townsend, on the northern end of the Olympic Peninsula, this gorgeous light deprivation greenhouse garden is producing beautiful flower and is home to some of the more exotic genetics in the Artizen brand. At 39,000 square feet it is the second largest of all of the gardens growing Artizen branded flower.
$IVDN: The latest news showed us new orders for Insultex House Wrap are being booked now. The best part of this news is that customers are starting to discover the superior performance of the product and they want it. New dealer Hamshaw Lumber has already placed their first purchase order with quick delivery from IVDN.
Innovative Designs Adds New England Retailer
Pittsburgh, PA, April 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs Inc. (OTCQB: IVDN), a company engaged in marketing and selling a unique insulated house wrap, has added Hamshaw Lumber to its retail list. Opened in 1980, Hamshaw Lumber now has seven locations: Barre, MA, Amherst, MA, Brattleboro, VT, South Deerfield, MA, Greenfield, MA, Keene, NH and Orange, MA.
Hamshaw Lumber buyer, Chris Calcari, commented, “A contractor and homeowner inquired about the Insultex House Wrap, with an R-Value of 6, at Hamshaw Lumber. After doing research, I was impressed with the energy efficiency it offers along with its environmental impact. Our first purchase order is in route to our Orange, Massachusetts store.” Innovative Designs CEO, Joseph Riccelli, commented, “We are pleased to begin doing business with Hamshaw Lumber. Their coverage in the New England area will open up opportunities for homebuilders and contractors to have easy access to our house wrap.”
About Innovative Designs Inc.
Innovative Designs Inc. manufactures the Insultex® House Wrap, Arctic Armor® Line, under the "i.d.i. gear" label featuring INSULTEX®. INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
Contact:
Joseph Riccelli
412-799-0350
joer@idigear.com
$GTCH The main aim of the application-specific, cybersecurity technology is to create secured level communications with the goal of serving military and governmental applications. The Infinia System is being developed with the goal of using a few types of encryptions/decryptions techniques, including authentication/authorization measures to ensure robust wireless network protection. The technology’s AI algorithms will automatically apply the best encryption/decryption technique according to application type, weather/terrain conditions and priorities. The Infinia System contemplates the incorporation of a deep learning module that will periodically change the exchanged keys to prevent a network interception, maintaining data integrity and real-time error correction. The techniques include implementation of symmetric and asymmetric encryption methodologies according to the network’s characteristics and nature. When fully implemented, it is believed that the system’s main advantage will be its analytics-based reasoning capabilities to elect the best cryptographic method to ensure robust security.
https://seekingalpha.com/pr/18690598-gbt-developing-proprietary-cryptographic-technology-designed-to-secure-long-range-radio
$GTCH GBT Roadmaps The Development of a Wearable Version for Its qTerm Device https://newsfilter.io/a/87d4022ff93dfa7e6a3f5489e6d3eb42
According to projections, the worldwide hemp industry would be worth $18.6 billion by 2027. As a result, investors and prospective shareholders of hemp-related enterprises are paying close attention. Endexx Corporation is a player in the industry, with a goal of having a presence in 20,000 store outlets. The company saw a spike recently, get in now!
https://www.influencive.com/endexx-corporation-dominating-the-market-with-its-hemp-derived-products
$GTCH "Our Apollo wireless motion detection patent was granted on April 12 and we are pleased to start R&D activities to evaluate its commercialization possibilities. The Apollo patent protects an advanced IP that we believe can be used as an efficient computer vision and in a wide variety of fields. We believe Apollo radio vision system can be used as a wearable-less health, “eyes” for smart vehicles or within a security system to detect concealed objects in airports. The patent’s intelligent computer vision can “see” through walls using machine learning algorithms. Based on RF data analysis, it constructs images and motion video of a scanned area. It is designed to detect and measure a heartbeat, breathing rhythm, a person’s fall, or emotional distress. I Since the technology works during day and night, we believe it can be an efficient technology within military and security applications. We considered Apollo as one of our major innovations and plan to conduct further research and development of intelligent systems based on its concepts.” Provided Danny Rittman, the Company’s CTO.
https://www.marketwatch.com/press-release/gbts-ai-based-motion-detection-wireless-patent-has-been-granted-2022-05-04?mod=mw_quote_news_seemore
$ITMC News: ITOCO acquires Colorful Euphoria, Lda to launch its "Soil Rescue Program" in Europe and Africa
TORONTO, ON / ACCESSWIRE / May 10, 2022 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce it has acquired 49 % of Colorful Euphoria, Lda.
Colorful Euphoria, Lda is a Portuguese company that operates via joint venture 100 hectares of farm land in the Alentejo region of Portugal. Itoco intends to expand this land position and create an Agro Park focused on advancing a "Soil Rescue Program".
Nopal Cactus are being grown effectively and profitably in this region with a focus on producing Prickly Pear juice concentrate.
Itoco and Colorful Euphoria have mutually developed a program whereby Nopal Cactus is introduced into an area as the first step toward overall land rehabilitation while at the same time creating sustainable profitable farming operations - "Soil Rescue Program".
The roots of the Nopal Cactus help water retention in the soil, thereby creating a crucial first step for other plants to grow. In a relatively short period of time, entire ecosystems can recover as water supplies stabilize.
In addition, programs of this type can create significant Carbon Credits. Nopal Cactus is very effective at removing carbon from the atmosphere permanently.
Itoco is capitalizing on Nopal farming innovations that leverage the Cacti's superb adaptation to dry and arid landscapes, which include fixing carbon dioxide at night and closing the spores (stomata) during the day, thus potentially earning producers carbon credits at an accelerated pace.
Nopal Cactus is able to trap up to 30 tons of carbon dioxide per hectare per year.
The Cactus is also able to offer strong vegetative cover against erosion or desertification while being able to tolerate a wide range of temperatures and to thrive in water limited environments. It is characterized by a wide-spreading fibrous roots system allowing it to access surface water and its succulent stems and pads store large quantities of water per hectare.
Itoco has purchased 49% of the shares of Colorful Euphoria for EUR ?5,000,000.00.
About ITOCO Inc:
ITOCO's mission is to be a global leader in developing, distributing, and producing Bio Tech related technologies and methodologies in a compliant environmentally friendly manner. ITOCO Inc. trades on the OTC Markets, symbol: ITMC. ITOCO is a 14-year-old publicly quoted specialty Bio Tech development, production and distribution company based in Toronto Canada and Nevada USA. ITOCO seeks to partner with outstanding individuals and companies within this field to joint venture, research, and co-develop Bio Tech related products and technologies to the market.
CONTACT:
Michael Paul, C.E.T.
President & CEO
ITOCO INC
ir@itoco.net
+1-800-805-1521
http://www.itoco.net
SOURCE: ITOCO Inc.
$GTCH Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/GTCH/cheat-sheet
$PVSP Artizen™ is now the 9th largest cannabis consumer brand in North America according to MJBiz Magazine, November 2021. Pervasip acquired the Artizen IP and made Artizen the first of possibly many consumer focused brands in our brand arsenal.
https://www.pervasip.net/artizen
$PVSP Intereactive Chart https://www.barchart.com/stocks/quotes/PVSP/interactive-chart
Real Stock Plays
Find a good online stock broker and open an account. Become familiarized with the layout and to take advantage of the free trading tools and research offered to clients only.
Some brokers offer virtual trading which is beneficial because you can trade with play money
Books provide a wealth of information and are inexpensive compared to the costs of classes, seminars, and educational DVDs sold across the web.
My personal all-time favorite is How to Make Money in Stocks by William O’Neil
Read articles
Articles are a fantastic resource for education. Recommended website for investment education: investopedia.com and Google search.
Forums can be another source for question and answer. The vast majority of participants are not professional traders, let alone profitable traders.
Heed advice from forums with a heavy dose of salt and do not, under any circumstance, follow trade recommendations.
Study the greats
Learning about the greatest investors of years past will provide perspective, inspiration, and appreciation for the game which is the stock market. Greats include Warren Buffett, Jesse Livermore, George Soros, Benjamin Graham, Peter Lynch, John Templeton and Paul Tudor Jones, among others. One of my favorite book series is the Market Wizards by Jack Schwager.
Read and follow the market
News sites such as Yahoo Finance and Google Finance serve as a great resource for new investors.
By monitoring the markets each day and reading headline stories investors can expose themselves to trends, 3rd party analysis, not to mention economic concepts and general business.
Pulling quotes and observing fundamental data can also be good.
courtesy of charting /\ wit tweezer top calls /\ Tony
@Montana_Trades
Really good study sheet on Candlestick Patterns
02-07-2021
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |